Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,836
archived clinical trials in
Leukemia

Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
Hematology and Oncology Associates of Northeastern Pennsylvania
mi
from
Scranton, PA
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
Hematology and Oncology Associates of Northeastern Pennsylvania
mi
from
Scranton, PA
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital Cancer Center - Scranton
mi
from
Scranton, PA
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital Cancer Center - Scranton
mi
from
Scranton, PA
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
Mount Nittany Medical Center
mi
from
State College, PA
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
Mount Nittany Medical Center
mi
from
State College, PA
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
U.T. Medical Center Cancer Institute
mi
from
Knoxville, TN
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
U.T. Medical Center Cancer Institute
mi
from
Knoxville, TN
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
Danville Regional Medical Center
mi
from
Danville, VA
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
Danville Regional Medical Center
mi
from
Danville, VA
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
UW Cancer Center Johnson Creek
mi
from
Johnson Creek, WI
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
UW Cancer Center Johnson Creek
mi
from
Johnson Creek, WI
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
Gundersen Lutheran Center for Cancer and Blood
mi
from
La Crosse, WI
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
Gundersen Lutheran Center for Cancer and Blood
mi
from
La Crosse, WI
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
Riverview Uw Cancer Center
mi
from
Wisconsin Rapids, WI
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
Riverview Uw Cancer Center
mi
from
Wisconsin Rapids, WI
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
Community Cancer Center
mi
from
Normal, IL
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
Community Cancer Center
mi
from
Normal, IL
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology Associates of Central Illinois, PC - Ottawa
mi
from
Ottawa, IL
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology Associates of Central Illinois, PC - Ottawa
mi
from
Ottawa, IL
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology Associates of Central Illinois, PC - Peoria
mi
from
Peoria, IL
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology Associates of Central Illinois, PC - Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
St. John's Regional Health Center
mi
from
Springfield, MO
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
St. John's Regional Health Center
mi
from
Springfield, MO
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
CCOP - Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
CCOP - Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Hospital
mi
from
Dayton, OH
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
CCOP - Dayton
mi
from
Dayton, OH
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
CCOP - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
Charles F. Kettering Memorial Hospital
mi
from
Kettering, OH
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
Charles F. Kettering Memorial Hospital
mi
from
Kettering, OH
Click here to add this to my saved trials
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Florida Hospital Cancer Institute at Florida Hospital Orlando
mi
from
Orlando, FL
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Florida Hospital Cancer Institute at Florida Hospital Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Dana-Farber/Brigham and Women's Cancer Center
mi
from
Boston, MA
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Dana-Farber/Brigham and Women's Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Monter Cancer Center of the North Shore-LIJ Health System
mi
from
Lake Success, NY
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Monter Cancer Center of the North Shore-LIJ Health System
mi
from
Lake Success, NY
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
CCOP - North Shore University Hospital
mi
from
Manhasset, NY
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
CCOP - North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Union Hospital of Cecil County
mi
from
Elkton, MD
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Union Hospital of Cecil County
mi
from
Elkton, MD
Click here to add this to my saved trials
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Symptom Burden in Chronic Myeloid Leukemia (CML)
Symptom Burden of Patients With Chronic Myeloid Leukemia (CML)
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Symptom Burden in Chronic Myeloid Leukemia (CML)
Symptom Burden of Patients With Chronic Myeloid Leukemia (CML)
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease
Status: Enrolling
Updated:  12/31/1969
New York Medical College
mi
from
Valhalla, NY
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease
Status: Enrolling
Updated: 12/31/1969
New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
A Feasibility Trial of Post-Transplant Infusion of Allogeneic Regulatory T Cells and Allogeneic Conventional T Cells in Patients With Hematologic Malignancies Undergoing Allogeneic Myeloablative Hematopoietic Cell Transplantation From Haploidentical-Related Donors
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
A Feasibility Trial of Post-Transplant Infusion of Allogeneic Regulatory T Cells and Allogeneic Conventional T Cells in Patients With Hematologic Malignancies Undergoing Allogeneic Myeloablative Hematopoietic Cell Transplantation From Haploidentical-Related Donors
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials